La curación de enfermedades sin tratamiento,
la regeneración de tejidos dañados por la vejez o por un traumatismo, la creación
de órganos listos para trasplante o la solución a trastornos genéticos son
algunos de los objetivos de la medicina regenerativa, una de las armas médicas
del futuro y un campo de estudio real en el presente.
La capacidad de la medicina regenerativa
con el uso de celuas madre, para generar células que puedan reemplazar a otras
enfermas y así corregir patologías, ha creado nuevas perspectivas para el tratamiento
de diferentes enfermedades con células madre adultas y podrían abrir las
puertas a una verdadera e importante "revolución" en el tratamiento
de enfermedades y evitar el envejecimiento.
Use of the stem cell mobilizer SE2® as part of conventional treatment on ankle injuries to expedite recovery in professional soccer players. (Preliminary report)
ResponderEliminarGarber, M1, Mazzoni, P2, Drapeau, C2; Gutierrez Viñuales, J3, Nazir, C1.
1. Clinica Quirurgica Quantum, Stem Cell deparment, Madrid, Spain
2. Stemtech International, Department of Research and Development, FL 33028, USA.
3. Medical Department, Rayo Majadahonda Football Club, Madrid, Spain
Background: Ankle injury is the most common injury for soccer players.
The number of peripheral blood stem cells (PBSC), is a key parameter in the speed and extent of recovery after an injury. In animal studies, stem cell mobilizer StemEnhance® shows accelerated muscle repair after induced muscle injury. Both StemEnhance® and its advanced formula SE2®, have been shown to trigger a significant increase in the number of PBSC.
Purpose: To determine whether SE2® could enhance the effectiveness of conventional treatment for sport ankle injuries.
Design: Randomized controlled trial; Level of evidence, 1.
Methods: Twelve male professional soccer players were randomly assigned, to either experimental (SE2®) or control group. Both groups received conventional treatment. The experimental group received 12 capsules of SE2® daily for a month. Patients were evaluated by the team's doctor with soft tissue sonograms at days 1, 7, 14 and 21. The Karlsson and Peterson Scoring System for Ankle function and Tegner activity level scale were taken every other day.
Results: The median severity of acute ankle injury was similar in both groups. The participants were pair matched, within the limits of the study. The SE2® group experienced a significantly greater reduction in pain, range of motion and joint stability compared with control group. Recovery time was on average 17 days for the SE2® group versus 21 days for the control group.
Conclusion: The use of the stem cell mobilizer SE2® in conjunction with conventional treatment reduced the recovery time from acute ankle injuries in male football players.